CTRI/2019/02/017481
尚未招募
未知
TRIHEXYPHENIDYL FOR TREATMENT OF DYSTONIA IN CHILDREN WITH CEREBRAL PALSY: A RANDOMIZED PLACEBO CONTROLLED TRIAL.
Abhishek S0 个研究点目标入组 0 人待定
概览
- 阶段
- 未知
- 干预措施
- 未指定
- 疾病 / 适应症
- Health Condition 1: G808- Other cerebral palsy
- 发起方
- Abhishek S
- 状态
- 尚未招募
- 最后更新
- 4年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •Residents of Delhi NCR
排除标准
- •1\.Children who have received Trihexyphenidyl, any other anti\-cholinergic or levodopa in last 3 months.
- •2\.Children who have required titration in their baclofen dosage in last 3 months.
- •3\.Poorly controlled epilepsy.
- •4\.Diagnosed cases of Glaucoma or Congenital Heart block.
- •5\.History of allergy or adverse reaction to anti\-cholinergic drugs in the past.
- •6\.History of orthopedic surgery or botulinum injection in last 6 months.
- •7\.Presence of features of contractures or hip dislocation.
结局指标
主要结局
未指定
相似试验
尚未招募
1 期
Effectiveness of the drug Trihexyphenidyl for abnormal movements in children with Cerebral PalsyCTRI/2018/01/011571Maulana Azad Medical College
已完成
2 期
Childhood Hypertonia of Central Origin: A Trial of Anticholinergic Treatment EffectsDystoniaNCT00122044University of Southern California35
招募中
1 期
Pharmacogenomic Contributions to Trihexyphenidyl Biotransformation and Response in Children With Dystonic Cerebral PalsyPediatric DisorderGenetic PredispositionDystonia, SecondaryDystoniaCerebral Palsy, Dystonic-RigidCerebral Palsy, DyskineticTrihexyphenidyl Adverse ReactionPharmacogenomic Drug InteractionNCT06554288Children's Mercy Hospital Kansas City40
尚未招募
不适用
Outcome of treatment with Triheptanoin in pediatric patients with long chain fatty acid oxidation disorders (LCFAODs)longchain fatty acid oxidation disorders (LCFAODs)longchain fatty acid oxidation disorders (LCFAODs), outcome, treatmentTCTR20210604002/A2
已完成
3 期
Addition of Pyridoxine to Prednisolone in Infantile SpasmsInfantile SpasmsNCT01828437Lady Hardinge Medical College62